Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01905046
Other study ID # A211102
Secondary ID U10CA031946NCI-2
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date November 23, 2015
Est. completion date November 2025

Study information

Verified date April 2024
Source Alliance for Clinical Trials in Oncology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized phase III trial studies metformin hydrochloride to see how well it works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of metformin hydrochloride may prevent breast cancer.


Description:

I. Test for the presence or absence of cytological atypia (as measured by a Masood Cytology Index Score of 14-17) in unilateral or bilateral random periareolar fine needle aspiration (RPFNA) aspirates after 12 and 24 months (24 month is optional for placebo-only group for patients who remain on placebo arm and will not receive metformin [metformin hydrochloride]) for women receiving metformin versus placebo control. The presence of cytological atypia means any atypia in any RPFNA specimen. SECONDARY OBJECTIVES: I. Use the Masood Cytology Index Score to test for the presence of cytological atypia or disappearance of cytological atypia in RPFNA aspirates after 12 months for both arms, and 24 months (24 month is optional for placebo-only group for patients who remain on placebo arm and will not receive metformin, and mandatory for crossover patients) for women receiving metformin 850 mg orally (PO) twice daily (BID) (metformin group). II. Compare Masood Cytology Score values at 0 and 12 months in right and left breasts (if both breasts were aspirated) from the same individual in the metformin and placebo group. III. Test the reproducibility of reverse phase protein microarray (RPPM) in duplicate RPPM determinations from individual RPFNA specimens. IV. Correlate baseline RPPM values with presence of atypia (as measured by Masood Cytology Index Score) at month 12 and month 24 (month 24 optional for placebo-only group; for patients who remain on placebo arm and will not receive metformin) RPFNA. TERTIARY OBJECTIVES: I. Test whether metformin alters RPFNA or blood biomarkers associated with breast cancer risk. II. Test whether metformin alters markers associated with obesity and insulin resistance. III. Test other exploratory measures in RPFNA and serum including metformin levels and estrogen/progesterone. IV. Banking: As part of ongoing research for Alliance Cancer Control studies, banking residual blood and RPFNA products for future studies.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 161
Est. completion date November 2025
Est. primary completion date November 10, 2023
Accepts healthy volunteers No
Gender Female
Age group 25 Years to 55 Years
Eligibility - PRE-REGISTRATION-INCLUSION CRITERIA - Must be at increased risk for breast cancer, defined as at least one of the following four criteria: - Having had a prior biopsy demonstrating atypical hyperplasia, lobular carcinoma in situ (LCIS), or ductal carcinoma in situ (DCIS) - A Gail Model Risk of >= 1.66% over 5 years - A strong family history of breast and/or ovarian cancer which is defined as at least one of the following: - One first-degree relative with breast cancer before the age of 50 years - One first degree relative with bilateral breast cancer - Two or more first-degree relatives with breast cancer - One first degree relative and two or more second or third degree relatives with breast cancer - One first-degree relative with breast cancer and one or more relatives with ovarian cancer - Two second or third degree relatives with either breast cancer and one or more with ovarian cancer - One second or third degree relative with breast cancer and two or more with ovarian cancer - Three or more second or third degree relatives with breast cancer - Known breast cancer (BRCA)1 or BRCA2 mutation carrier providing that the woman has - Met with a genetic counselor to review genetic testing results, and - Has been offered the opportunity to undergo prophylactic mastectomy and oophorectomy - Pre-menopausal women as defined as four menstrual cycles within the last six months prior to pre-registration; women with less than 4 menses within 6 months prior to pre-registration, or women who have had a hysterectomy with ovaries intact will be considered premenopausal if follicle-stimulating hormone (FSH) level is < 20; women who are using hormonal contraceptives that cause amenorrhea (e.g. injectable and extended oral contraceptives, hormone containing contraceptive ring, or hormone containing intrauterine device) will be considered eligible if they had a minimum of 4 menstrual cycles within the last six months prior to starting on the contraceptive - Digital mammogram within 365 days prior to pre-registration - Mammograms must be read as not suspicious for breast cancer (American College of Rheumatology [ACR] class I-III); subjects with a class IV mammogram may be enrolled once they have been evaluated by a breast surgeon and there is no evidence of invasive malignancy - Must be non-pregnant and non-lactating for at least one year prior to pre-registration - If currently menstruating, subjects must use a reliable method of birth control - Willing to provide RPFNA and blood samples for correlative research purposes - REGISTRATION/RANDOMIZATION INCLUSION CRITERIA: - Qualifying cytological atypia in RPFNA, Masood score of 14-17; the qualifying RPFNA (of one or both breasts) must be send to Dr. Seewaldt's laboratory for cytological scoring and proteomic analysis; score results must be received from Dr. Seewaldt's lab prior to patient registration/randomization; test must be done =< 90 days prior to registration/randomization * Note: Only the contralateral breast can be aspirated in women with DCIS and those undergoing surgery for an atypical lesion; the decision to aspirate the contralateral breast is at the discretion of the woman's surgeon - Hemoglobin >= 9 g/dL - Absolute neutrophil count (ANC) >= 1500/mm^3 - Platelet count >= 75,000/mm^3 - Creatinine =< 1.4 mg/dL - Total bilirubin =< 3.0 mg/dL - Aspartate transaminase (AST) =< 3 x upper limit of normal (ULN) - Alanine transaminase (ALT) =< 3 x ULN - Negative pregnancy test done =< 7 days prior to registration/randomization, for women of childbearing potential only * A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months) - Women eligible to take tamoxifen must be offered tamoxifen prevention as part of their clinical care and have refused tamoxifen treatment Exclusion Criteria - Other active malignancy =< 5 years prior to pre-registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history or prior malignancy, they must not be receiving other specific treatment, i.e., other hormonal therapy, for their cancer - Body mass index (BMI) < 25 - Receiving Warfarin - Bilateral breast implants or autologous breast flap reconstruction - Active diagnosis of alcoholism - Contraindication to metformin prevention such as acute hypersensitivity or allergic reaction to metformin - Currently receiving tamoxifen or raloxifene - Administration of any investigational agent =< 30 days prior to pre-registration - Previous radiation to both breasts - Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Receiving pyrimethamine, cimetidine, rifampin or cephalexin - Women who have a core biopsy or excisional biopsy containing invasive cancer - Women who have taken metformin within the past 90 days - Patients with hemoglobin a1c > 6.3 or who are being actively treated for diabetes

Study Design


Intervention

Drug:
metformin hydrochloride
given PO
Other:
placebo
given PO

Locations

Country Name City State
United States Prisma Health Cancer Institute - Spartanburg Boiling Springs South Carolina
United States Roswell Park Cancer Institute Buffalo New York
United States The Christ Hospital Cincinnati Ohio
United States Ohio State University Comprehensive Cancer Center Columbus Ohio
United States City of Hope Comprehensive Cancer Center Duarte California
United States Duke University Medical Center Durham North Carolina
United States Prisma Health Cancer Institute - Easley Easley South Carolina
United States Greenville Health System Cancer Institute-Andrews Greenville South Carolina
United States Prisma Health Cancer Institute - Butternut Greenville South Carolina
United States Prisma Health Cancer Institute - Eastside Greenville South Carolina
United States Prisma Health Cancer Institute - Faris Greenville South Carolina
United States Prisma Health Greenville Memorial Hospital Greenville South Carolina
United States Prisma Health Cancer Institute - Greer Greer South Carolina
United States M D Anderson Cancer Center Houston Texas
United States University of Kansas Cancer Center Kansas City Kansas
United States Doctor's Hospital of Laredo Laredo Texas
United States Los Angeles County-USC Medical Center Los Angeles California
United States USC / Norris Comprehensive Cancer Center Los Angeles California
United States University of Wisconsin Carbone Cancer Center Madison Wisconsin
United States The Community Hospital Munster Indiana
United States Mount Sinai Hospital New York New York
United States NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York New York
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States Mayo Clinic in Rochester Rochester Minnesota
United States Prisma Health Cancer Institute - Seneca Seneca South Carolina
United States City of Hope South Pasadena South Pasadena California
United States Cotton O'Neil Cancer Center / Stormont Vail Health Topeka Kansas

Sponsors (2)

Lead Sponsor Collaborator
Alliance for Clinical Trials in Oncology National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Test for the presence or absence of cytological atypia in unilateral or bilateral RPFNA aspirates after 12 and 24 months (24 month is optional for placebo-only group for patients who remain on placebo arm and will not receive metformin). Up to 24 months
Secondary Test for the Masood Score and the presence of atypia or disapperance of atypia in RPFNA after 12 months (for both arms) and 24 months for Metformin arm. Up to 24 months
Secondary Compare Masood Cytology Score value at 0 and 12 in right and left breast from the same individual in the metformin and non-metformin group. Up to 24 months
Secondary Test the reproducibility of RPPM in duplicate RPPM determinations from individual RPFNA specimens. Up to 12 months
Secondary Correlate baseline RPPM values with presence of atypia at Month 12 and Month 24. Up to 24 months
See also
  Status Clinical Trial Phase
Completed NCT02314156 - Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Phase 2
Completed NCT01874184 - Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer N/A
Completed NCT01869764 - Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer Phase 2
Completed NCT02587663 - Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI N/A
Active, not recruiting NCT04537312 - Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM) N/A
Active, not recruiting NCT01245712 - Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer Phase 2
Recruiting NCT02993159 - Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast Phase 2
Completed NCT01753908 - Broccoli Sprout Extract in Treating Patients With Breast Cancer Early Phase 1
Terminated NCT02023008 - Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy N/A
Terminated NCT01754519 - Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery Phase 2
Completed NCT01849250 - Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors Phase 2
Completed NCT01819233 - Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy N/A
Active, not recruiting NCT03077841 - Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer Phase 2/Phase 3
Active, not recruiting NCT02352883 - MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ N/A
Recruiting NCT03909282 - Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma N/A
Completed NCT01723943 - Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients N/A
Completed NCT00637481 - A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer Phase 1
Completed NCT01975363 - Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer N/A
Active, not recruiting NCT03391388 - 3D-CRT, Proton, or Brachytherapy APBI in Treating Patients With Invasive and Non-invasive Breast Cancer Phase 2
Completed NCT02526498 - Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery Phase 2